Incyte (INCY)
(Delayed Data from NSDQ)
$65.74 USD
-1.08 (-1.62%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $65.63 -0.11 (-0.17%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Price, Consensus and EPS Surprise
INCY 65.74 -1.08(-1.62%)
Will INCY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for INCY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INCY
Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?
Incyte Announces Promising New Data on Oncology Candidate at ESMO
INCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?
Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?
Why Is Glaxo (GSK) Up 10.3% Since Last Earnings Report?
Other News for INCY
Syndax Pharmaceuticals: Navigating Through A Pivotal Year
Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo? (axatilimab-csfr) in Chronic Graft-Versus-Host Disease
Incyte downgraded at Truist on Jakafi patent cliff
Wall Street Lower Ahead Of Interest Rate Move
Nvidia, ARM initiated: Wall Street's top analyst calls